Pharmacogenomics of opioids: an investigation of the genetic determinants of variability in analgesic response to opioids

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN35444083

Enrollment

100

Registered

2004-09-30

Start date

2003-10-01

Completion date

Unknown

Last updated

2016-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesic response to opioids Signs and Symptoms Analgesic response to opioids

Interventions

Randomised, blinded (Phase 2). Each subject will act as their own control. On visit one, subjects will be randomised to receive either intravenous morphine or intravenous saline (placebo). They will

Eligibility

Inclusion criteria

Inclusion criteria: Total number RMH patients 100

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026